Report Summary
Eternity Insights has published a new study on Global Asia-Pacific Cannabidiol (CBD) Market focusing on key segments as by Type (Food Grade, Pharmaceutical Grade, Other), by Application (Anxiety, Fibromyalgia (FM), Diabetes, Other), and by region. This deep dive re-search report highlights the market and competitive intelligence across the key segments of the mar-ket. The report also considers the impact of COVID-19 on the global Asia-Pacific Cannabidiol (CBD) Market.
The report considers 2018-2020 as historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the market drivers, challenges, and trends to accurately map the market scenario and competition. Moreover, key insights related to market having direct impact on the market will also be covered.
Asia-Pacific Cannabidiol (CBD) Market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
Global Asia-Pacific Cannabidiol (CBD) Market Size, 2018-2028 (USD Million)
To learn more about this report
Global Asia-Pacific Cannabidiol (CBD) Market Segmentation:
Asia-Pacific Cannabidiol (CBD) Market, By Type
- Food Grade
- Pharmaceutical Grade
- Other
Asia-Pacific Cannabidiol (CBD) Market, By Application
- Anxiety
- Fibromyalgia (FM)
- Diabetes
- Other
To learn more about this report
Geographically, the market is categorized in to five regions as North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America region dominates the global Asia-Pacific Cannabidiol (CBD) market in terms of demand generation. The Asia-Pacific Cannabidiol (CBD) market in Asia Pacific region is expected to grow at significantly high growth rate. The regional market is further sub-segmented and analyzed at granular level across key countries. The report will include market size and forecast for Asia-Pacific Cannabidiol (CBD) market for below listed coun-tries across each region.
North America (U.S. and Canada), Europe (Germany, France, Italy, UK, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, and Rest of Asia Pacific region); Latin America (Brazil, Mexico, and rest of the Latin America); Middle East and Africa (GCC, South Africa, and Rest of the Middle East and Africa).
Global Asia-Pacific Cannabidiol (CBD) Market Taxonomy:
To learn more about this report
Global Asia-Pacific Cannabidiol (CBD) Market Competitive Landscape
The global Asia-Pacific Cannabidiol (CBD) market analysis report covers detailed analysis of competitive scenario across globe. The report includes profiles of leading players covering below details
- Company Overview
- Financial Analysis
- Product Portfolio Analysis
- Strategic Overview
- SWOT Analysis
List of Companies Profiled in the report:
- ENDOCA
- CBD American Shaman
- Gaia Botanicals
- Isodiol
- Medical Marijuana
- Aurora Cannabis (AC)
- Cannoid
- Canopy Growth Corporation
- CV Sciences
- IRIE CBD
- Elixinol
- NuLeaf Naturals
- PharmaHemp
- Folium Biosciences
- Other Players of Specific Interest can be added based on requirement
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Food Grade, Pharmaceutical Grade, Other |
| By Application Outlook |
Anxiety, Fibromyalgia (FM), Diabetes, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
ENDOCA, CBD American Shaman, Gaia Botanicals, Isodiol, Medical Marijuana, Aurora Cannabis (AC), Cannoid, Canopy Growth Corporation, CV Sciences, IRIE CBD, Elixinol, NuLeaf Naturals, PharmaHemp, Folium Biosciences |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Benefits to the stake holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
Table Of Contents
Table of Contents
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Cannabidiol (CBD) Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Analysis by Types
2.1 Overall Market Performance(Volume)
2.1.1 Food Grade Market Performance (Volume)
2.1.2 Pharmaceutical Grade Market Performance (Volume)
2.2 Overall Market Performance(Value)
2.2.1 Food Grade Market Performance (Value)
2.2.2 Pharmaceutical Grade Market Performance (Value)
3 Product Application Market
3.1 Overall Market Performance (Volume)
3.1.1 Anxiety Market Performance (Volume)
3.1.2 Fibromyalgia (FM) Market Performance (Volume)
3.1.3 Diabetes Market Performance (Volume)
3.1.4 Other Market Performance (Volume)
4 Manufacturers Profiles/Analysis
4.1 ENDOCA
4.1.1 ENDOCA Profiles
4.1.2 ENDOCA Product Information
4.1.3 ENDOCA Cannabidiol (CBD) Business Performance
4.1.4 ENDOCA Cannabidiol (CBD) Business Development and Market Status
4.2 CBD American Shaman
4.2.1 CBD American Shaman Profiles
4.2.2 CBD American Shaman Product Information
4.2.3 CBD American Shaman Cannabidiol (CBD) Business Performance
4.2.4 CBD American Shaman Cannabidiol (CBD) Business Development and Market Status
4.3 Gaia Botanicals
4.3.1 Gaia Botanicals Profiles
4.3.2 Gaia Botanicals Product Information
4.3.3 Gaia Botanicals Cannabidiol (CBD) Business Performance
4.3.4 Gaia Botanicals Cannabidiol (CBD) Business Development and Market Status
4.4 Isodiol
4.4.1 Isodiol Profiles
4.4.2 Isodiol Product Information
4.4.3 Isodiol Cannabidiol (CBD) Business Performance
4.4.4 Isodiol Cannabidiol (CBD) Business Development and Market Status
4.5 Medical Marijuana
4.5.1 Medical Marijuana Profiles
4.5.2 Medical Marijuana Product Information
4.5.3 Medical Marijuana Cannabidiol (CBD) Business Performance
4.5.4 Medical Marijuana Cannabidiol (CBD) Business Development and Market Status
4.6 Aurora Cannabis (AC)
4.6.1 Aurora Cannabis (AC) Profiles
4.6.2 Aurora Cannabis (AC) Product Information
4.6.3 Aurora Cannabis (AC) Cannabidiol (CBD) Business Performance
4.6.4 Aurora Cannabis (AC) Cannabidiol (CBD) Business Development and Market Status
4.7 Cannoid
4.7.1 Cannoid Profiles
4.7.2 Cannoid Product Information
4.7.3 Cannoid Cannabidiol (CBD) Business Performance
4.7.4 Cannoid Cannabidiol (CBD) Business Development and Market Status
4.8 Canopy Growth Corporation
4.8.1 Canopy Growth Corporation Profiles
4.8.2 Canopy Growth Corporation Product Information
4.8.3 Canopy Growth Corporation Cannabidiol (CBD) Business Performance
4.8.4 Canopy Growth Corporation Cannabidiol (CBD) Business Development and Market Status
4.9 CV Sciences
4.9.1 CV Sciences Profiles
4.9.2 CV Sciences Product Information
4.9.3 CV Sciences Cannabidiol (CBD) Business Performance
4.9.4 CV Sciences Cannabidiol (CBD) Business Development and Market Status
4.10 IRIE CBD
4.10.1 IRIE CBD Profiles
4.10.2 IRIE CBD Product Information
4.10.3 IRIE CBD Cannabidiol (CBD) Business Performance
4.10.4 IRIE CBD Cannabidiol (CBD) Business Development and Market Status
4.11 Elixinol
4.12 NuLeaf Naturals
4.13 PharmaHemp
4.14 Folium Biosciences
5 Market Performance for Manufacturers
5.1 Asia-Pacific Cannabidiol (CBD) Sales (K Units) and Market Share by Manufacturers 2014-2020
5.2 Asia-Pacific Cannabidiol (CBD) Revenue (M USD) and Market Share by Manufacturers 2014-2020
5.3 Asia-Pacific Cannabidiol (CBD) Price (USD/Unit) of Manufacturers 2014-2020
5.4 Asia-Pacific Cannabidiol (CBD) Gross Margin of Manufacturers 2014-2020
5.5 Market Concentration
6 Regions Market Performance for Manufacturers
6.1 China Market Performance for Manufacturers
6.1.1 China Cannabidiol (CBD) Sales (K Units) and Share of Manufacturers 2014-2020
6.1.2 China Cannabidiol (CBD) Revenue (M USD) and Share of Manufacturers 2014-2020
6.1.3 China Cannabidiol (CBD) Price (USD/Unit) of Manufacturers 2014-2020
6.1.4 China Cannabidiol (CBD) Gross Margin of Manufacturers 2014-2020
6.1.5 Market Concentration
6.2 Japan Market Performance for Manufacturers
6.2.1 Japan Cannabidiol (CBD) Sales (K Units) and Share of Manufacturers 2014-2020
6.2.2 Japan Cannabidiol (CBD) Revenue (M USD) and Share of Manufacturers 2014-2020
6.2.3 Japan Cannabidiol (CBD) Price (USD/Unit) of Manufacturers 2014-2020
6.2.4 Japan Cannabidiol (CBD) Gross Margin of Manufacturers 2014-2020
6.2.5 Market Concentration
6.3 South Korea Market Performance for Manufacturers
6.3.1 South Korea Cannabidiol (CBD) Sales (K Units) and Share of Manufacturers 2014-2020
6.3.2 South Korea Cannabidiol (CBD) Revenue (M USD) and Share of Manufacturers 2014-2020
6.3.3 South Korea Cannabidiol (CBD) Price (USD/Unit) of Manufacturers 2014-2020
6.3.4 South Korea Cannabidiol (CBD) Gross Margin of Manufacturers 2014-2020
6.3.5 Market Concentration
6.4 India Market Performance for Manufacturers
6.4.1 India Cannabidiol (CBD) Sales (K Units) and Share of Manufacturers 2014-2020
6.4.2 India Cannabidiol (CBD) Revenue (M USD) and Share of Manufacturers 2014-2020
6.4.3 India Cannabidiol (CBD) Price (USD/Unit) of Manufacturers 2014-2020
6.4.4 India Cannabidiol (CBD) Gross Margin of Manufacturers 2014-2020
6.4.5 Market Concentration
6.5 Southeast Asia Market Performance for Manufacturers
6.5.1 Southeast Asia Cannabidiol (CBD) Sales (K Units) and Share of Manufacturers 2014-2020
6.5.2 Southeast Asia Cannabidiol (CBD) Revenue (M USD) and Share of Manufacturers 2014-2020
6.5.3 Southeast Asia Cannabidiol (CBD) Price (USD/Unit) of Manufacturers 2014-2020
6.5.4 Southeast Asia Cannabidiol (CBD) Gross Margin of Manufacturers 2014-2020
6.5.5 Market Concentration
6.6 Australia Market Performance for Manufacturers
6.6.1 Australia Cannabidiol (CBD) Sales (K Units) and Share of Manufacturers 2014-2020
6.6.2 Australia Cannabidiol (CBD) Revenue (M USD) and Share of Manufacturers 2014-2020
6.6.3 Australia Cannabidiol (CBD) Price (USD/Unit) of Manufacturers 2014-2020
6.6.4 Australia Cannabidiol (CBD) Gross Margin of Manufacturers 2014-2020
6.6.5 Market Concentration
6.7 Market Performance for Manufacturers
6.7.1 Cannabidiol (CBD) Sales (K Units) and Share of Manufacturers 2014-2020
6.7.2 Cannabidiol (CBD) Revenue (M USD) and Share of Manufacturers 2014-2020
6.7.3 Cannabidiol (CBD) Price (USD/Unit) of Manufacturers 2014-2020
6.7.4 Cannabidiol (CBD) Gross Margin of Manufacturers 2014-2020
6.7.5 Market Concentration
6.8 Market Performance for Manufacturers
6.8.1 Cannabidiol (CBD) Sales (K Units) and Share of Manufacturers 2014-2020
6.8.2 Cannabidiol (CBD) Revenue (M USD) and Share of Manufacturers 2014-2020
6.8.3 Cannabidiol (CBD) Price (USD/Unit) of Manufacturers 2014-2020
6.8.4 Cannabidiol (CBD) Gross Margin of Manufacturers 2014-2020
6.8.5 Market Concentration
7 Asia-Pacific Cannabidiol (CBD) Market Performance (Sales)
7.1 Asia-Pacific Cannabidiol (CBD) Sales (K Units) and Market Share by Regions 2014-2020
7.2 Asia-Pacific Cannabidiol (CBD) Revenue (M USD) and Market Share by Regions 2014-2020
7.3 Asia-Pacific Cannabidiol (CBD) Price (USD/Unit) by Regions 2014-2020
7.4 Asia-Pacific Cannabidiol (CBD) Gross Margin by Regions 2014-2020
8 Development Trend for Regions (Sales)
8.1 Asia-Pacific Cannabidiol (CBD) Sales and Growth, Sales Value and Growth Rate2014-2020
8.2 China Cannabidiol (CBD) Sales and Growth, Sales Value and Growth Rate 2014-2020
8.3 Japan Cannabidiol (CBD) Sales and Growth, Sales Value and Growth Rate 2014-2020
8.4 South Korea Cannabidiol (CBD) Sales and Growth, Sales Value and Growth Rate 2014-2020
8.5 India Cannabidiol (CBD) Sales and Growth, Sales Value and Growth Rate 2014-2020
8.6 Southeast Asia Cannabidiol (CBD) Sales and Growth, Sales Value and Growth Rate 2014-2020
8.7 Australia Cannabidiol (CBD) Sales and Growth, Sales Value and Growth Rate 2014-2020
9 Upstream Source, Technology and Cost
9.1 Upstream Source
9.2 Technology
9.3 Cost
10 Channel Analysis
10.1 Market Channel
10.2 Distributors
11 Consumer Analysis
11.1 Anxiety Industry
11.2 Fibromyalgia (FM) Industry
11.3 Diabetes Industry
12 Market Forecast 2021-2026
12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2021-2026
12.1.1 Asia-Pacific Cannabidiol (CBD) Sales (K Units), Revenue (M USD) and Market Share by Regions 2021-2026
12.1.2 Asia-Pacific Cannabidiol (CBD) Sales (K Units) and Growth Rate 2021-2026
12.1.3 China Cannabidiol (CBD) Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.4 Japan Cannabidiol (CBD) Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.5 South Korea Cannabidiol (CBD) Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.6 India Cannabidiol (CBD) Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.7 Southeast Asia Cannabidiol (CBD) Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.1.8 Australia Cannabidiol (CBD) Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2 Sales (K Units) and Revenue (M USD) Forecast by Types 2021-2026
12.2.1 Overall Market Performance
12.2.2 Food Grade Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.2.3 Pharmaceutical Grade Sales (K Units), Revenue (M USD) and Growth Rate 2021-2026
12.3 Sales and Growth Rate Forecast by Application 2021-2026
12.3.1 Overall Market Performance
12.3.2 Anxiety
12.3.3 Fibromyalgia (FM)
12.3.4 Diabetes
12.3.5 Other
12.4 Price (USD/Unit) and Gross Profit Forecast
12.4.1 Asia-Pacific Cannabidiol (CBD) Price (USD/Unit) Trend 2021-2026
12.4.2 Asia-Pacific Cannabidiol (CBD) Gross Profit Trend 2021-2026
13 Conclusion
